Year: 2022

syncromune_logo_10.20.21

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Immunotherapy Platform

FORT LAUDERDALE, Fla. & BEIJING--(BUSINESS WIRE)--#immunotherapy--Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy...

Kenneth-Research

Global Drug Delivery Systems Market to Generate a Significant Revenue by 2033 and to Grow at a CAGR of ~10% During 2023-2033; Growing Immunization Against Infectious Illnesses to Elevate Market Growth – Kenneth Research

logo-91

China $5.2+ Bn Electric Vehicle Charging Infrastructure Markets, Analysis, Competition, Forecast & Opportunities, 2017-2021 & 2022-2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Electric Vehicle Charging Infrastructure Market By Vehicle Type, By Type, By Charging Mode, By Installed Location, By...

logo-90

China Autonomous Driving Data Closed Loop Research Report 2022 Featuring 6 Typical Data Acquisition and Annotation Companies, 9 Data Closed Loop Solution Providers and Layout of 18 Tier1/2 Suppliers – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Autonomous Driving Data Closed Loop Research Report, 2022" report has been added to ResearchAndMarkets.com's offering. The development...